Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli

Completed · Early Phase 1 · Has a placebo group

Conditions studied: Pruritus, Skin Disorder

In brief

The objective of this double-blinded placebo-controlled cross-over study is to define the role of the over the counter agent, N-acetyl cysteine (NAC), in mitigating the development of pruritus (skin itching). The study is designed to have all subjects treated with a seven-day regimen of both NAC and placebo. NAC will be prescribed at a dose of 1,500 mg twice daily for seven days. Subjects will initially be randomly assigned (1:1) to either the NAC or placebo arm of the study, before crossing over to the opposite arm after completing a minimum of 30-day washout period. The study will encompass a period of approximately 11 weeks (about 2 and a half months).

Key facts

Study ID
NCT05287724
Run by
Wright State University
People needed
20
Starts
2022-06-19
Expected to finish
2024-01-04
Last updated by the study team
2024-03-06

Who can join

Age: 18 and older, up to 40. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.